New PET scan could reveal kidney cancer drug success in weeks, not months
NCT ID NCT01582204
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study tests whether a new type of PET scan using a radioactive antibody called 124I-cG250 can detect if kidney cancer is responding to targeted therapy (sunitinib or pazopanib) earlier than standard CT scans. The antibody attaches to a protein found on kidney cancer cells, making them visible on the scan. Researchers hope this approach can predict treatment success within the first month, instead of waiting several months for tumor shrinkage on a CT scan. The trial involves 17 adults with advanced clear cell kidney cancer who are about to start standard targeted therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 124I-cG250
- What this could lead to
- If successful, this imaging method could allow doctors to see whether a kidney cancer drug is working weeks earlier than standard scans, helping tailor treatment faster.
- What could go wrong
- This is a small pilot study with only 17 participants, so results may not apply broadly. The scan involves a radioactive tracer, and its accuracy compared to standard methods is still unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Kidney tumor ablation: does it destroy cancer and boost well-being?
- New scan could reveal hidden kidney cancer
- Blood test aims to spot hidden cancer cells in 9 tumor types
- Cancer-Killing virus plus immunotherapy shows promise in kidney cancer trial